Karyopharm Therapeutics Inc. has submitted a New Drug Application to FDA, seeking accelerated approval for Xpovio (selinexor), the company’s first-in-class, oral selective inhibitor of nuclear export (SINE) compound, as a new treatment for patients with relapsed or refractory diffuse large B-Cell lymphoma after at least two prior multi-agent therapies and who are ineligible for stem cell transplantation, including CAR-T cell therapy.
In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL).
